uniQure N.V. announced preliminary data from the first cohort of its Phase I/IIa clinical trial for AMT-260, targeting refractory mesial temporal lobe epilepsy. In the low-dose cohort (1x10 12 gc/mL), three of six patients achieved 79% to 100% reductions in disabling seizures during months four through six of follow-up. The remaining three patients showed variable changes in disabling seizures, ranging from a 33% decrease to a 36% increase. No serious adverse events related to AMT-260 or the surgical procedure were reported as of June 19, 2026. uniQure N.V. is a biotechnology company focused on gene therapy development.
